CN116617132A - 一种抗衰组合物及其应用 - Google Patents
一种抗衰组合物及其应用 Download PDFInfo
- Publication number
- CN116617132A CN116617132A CN202310608412.2A CN202310608412A CN116617132A CN 116617132 A CN116617132 A CN 116617132A CN 202310608412 A CN202310608412 A CN 202310608412A CN 116617132 A CN116617132 A CN 116617132A
- Authority
- CN
- China
- Prior art keywords
- parts
- aging
- extract
- product
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003712 anti-aging effect Effects 0.000 title claims abstract description 108
- 239000000203 mixture Substances 0.000 title claims abstract description 48
- 238000002156 mixing Methods 0.000 claims abstract description 31
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 31
- 238000003756 stirring Methods 0.000 claims abstract description 29
- 239000004480 active ingredient Substances 0.000 claims abstract description 20
- 239000000419 plant extract Substances 0.000 claims abstract description 16
- 238000010438 heat treatment Methods 0.000 claims abstract description 15
- 239000002904 solvent Substances 0.000 claims abstract description 11
- 239000003755 preservative agent Substances 0.000 claims abstract description 10
- 230000002335 preservative effect Effects 0.000 claims abstract description 10
- 238000001816 cooling Methods 0.000 claims abstract description 9
- 239000004519 grease Substances 0.000 claims abstract description 9
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- 239000000047 product Substances 0.000 claims description 95
- 239000000284 extract Substances 0.000 claims description 48
- 239000003921 oil Substances 0.000 claims description 26
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 26
- 238000000855 fermentation Methods 0.000 claims description 24
- 230000004151 fermentation Effects 0.000 claims description 24
- 235000019198 oils Nutrition 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Natural products CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 18
- 239000011259 mixed solution Substances 0.000 claims description 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 17
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims description 15
- 229920001184 polypeptide Polymers 0.000 claims description 15
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims description 14
- 239000004475 Arginine Substances 0.000 claims description 14
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 claims description 14
- 108010087806 Carnosine Proteins 0.000 claims description 14
- 239000004472 Lysine Substances 0.000 claims description 14
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 14
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 claims description 14
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 14
- 229940044199 carnosine Drugs 0.000 claims description 14
- 239000000463 material Substances 0.000 claims description 14
- 239000004378 Glycyrrhizin Substances 0.000 claims description 13
- 241000121220 Tricholoma matsutake Species 0.000 claims description 13
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 claims description 13
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims description 13
- 229960004949 glycyrrhizic acid Drugs 0.000 claims description 13
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims description 13
- 235000019410 glycyrrhizin Nutrition 0.000 claims description 13
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 13
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 12
- LFYJSSARVMHQJB-UHFFFAOYSA-N Backuchiol Natural products CC(C)=CCCC(C)(C=C)C=CC1=CC=C(O)C=C1 LFYJSSARVMHQJB-UHFFFAOYSA-N 0.000 claims description 12
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims description 12
- 241000222336 Ganoderma Species 0.000 claims description 12
- 241000186660 Lactobacillus Species 0.000 claims description 12
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 12
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 12
- LFYJSSARVMHQJB-GOSISDBHSA-N bakuchinol Natural products CC(C)=CCC[C@@](C)(C=C)C=CC1=CC=C(O)C=C1 LFYJSSARVMHQJB-GOSISDBHSA-N 0.000 claims description 12
- LFYJSSARVMHQJB-QIXNEVBVSA-N bakuchiol Chemical compound CC(C)=CCC[C@@](C)(C=C)\C=C\C1=CC=C(O)C=C1 LFYJSSARVMHQJB-QIXNEVBVSA-N 0.000 claims description 12
- 229940117895 bakuchiol Drugs 0.000 claims description 12
- KXXXNMZPAJTCQY-UHFFFAOYSA-N bakuchiol Natural products CC(C)CCCC(C)(C=C)C=Cc1ccc(O)cc1 KXXXNMZPAJTCQY-UHFFFAOYSA-N 0.000 claims description 12
- 239000002454 curcuma longa l. root extract Substances 0.000 claims description 12
- 239000000706 filtrate Substances 0.000 claims description 12
- 229940089468 hydroxyethylpiperazine ethane sulfonic acid Drugs 0.000 claims description 12
- 229940039696 lactobacillus Drugs 0.000 claims description 12
- 229940101267 panthenol Drugs 0.000 claims description 12
- 239000011619 pantothenol Substances 0.000 claims description 12
- 235000020957 pantothenol Nutrition 0.000 claims description 12
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 12
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 12
- WSGCRSMLXFHGRM-DEVHWETNSA-N (2s)-2-[[(2s)-6-amino-2-[[(2s,3r)-2-[[(2s,3r)-2-[[(2s)-6-amino-2-(hexadecanoylamino)hexanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]hexanoyl]amino]-3-hydroxypropanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O WSGCRSMLXFHGRM-DEVHWETNSA-N 0.000 claims description 11
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 11
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 11
- 239000002994 raw material Substances 0.000 claims description 11
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims description 10
- 235000019441 ethanol Nutrition 0.000 claims description 10
- BXOCHUWSGYYSFW-HVWOQQCMSA-N spilanthol Chemical compound C\C=C\C=C/CC\C=C\C(=O)NCC(C)C BXOCHUWSGYYSFW-HVWOQQCMSA-N 0.000 claims description 10
- IHRKJQSLKLYWBQ-QKDODKLFSA-N (2s)-2-[[(2s)-1-[(2s)-5-amino-2-[[2-(hexadecanoylamino)acetyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O IHRKJQSLKLYWBQ-QKDODKLFSA-N 0.000 claims description 9
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims description 9
- 235000011187 glycerol Nutrition 0.000 claims description 9
- 229960002446 octanoic acid Drugs 0.000 claims description 9
- 229940094946 palmitoyl tetrapeptide-7 Drugs 0.000 claims description 9
- 240000001548 Camellia japonica Species 0.000 claims description 8
- 235000004433 Simmondsia californica Nutrition 0.000 claims description 8
- 235000018597 common camellia Nutrition 0.000 claims description 8
- 239000008367 deionised water Substances 0.000 claims description 8
- 229910021641 deionized water Inorganic materials 0.000 claims description 8
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 claims description 8
- XLPLFRLIWKRQFT-XUJYDZMUSA-N (3,3-dimethyl-2-oxobutyl) (2e,4e,6e,8e)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoate Chemical compound CC(C)(C)C(=O)COC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C XLPLFRLIWKRQFT-XUJYDZMUSA-N 0.000 claims description 7
- ANZUDYZHSVGBRF-UHFFFAOYSA-N 3-ethylnonane-1,2,3-triol Chemical compound CCCCCCC(O)(CC)C(O)CO ANZUDYZHSVGBRF-UHFFFAOYSA-N 0.000 claims description 7
- BYUQATUKPXLFLZ-UIOOFZCWSA-N CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 Chemical compound CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 BYUQATUKPXLFLZ-UIOOFZCWSA-N 0.000 claims description 7
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 7
- 229940093441 palmitoyl oligopeptide Drugs 0.000 claims description 7
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 claims description 7
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 claims description 6
- -1 hydroxy pinacolone retinoic acid ester Chemical class 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 6
- BXOCHUWSGYYSFW-UHFFFAOYSA-N all-trans spilanthol Natural products CC=CC=CCCC=CC(=O)NCC(C)C BXOCHUWSGYYSFW-UHFFFAOYSA-N 0.000 claims description 5
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims description 4
- 241000723346 Cinnamomum camphora Species 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 239000003974 emollient agent Substances 0.000 claims description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims description 3
- 229930002330 retinoic acid Natural products 0.000 claims description 3
- 229940032094 squalane Drugs 0.000 claims description 3
- 229960001727 tretinoin Drugs 0.000 claims description 3
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims description 2
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 claims description 2
- 235000019082 Osmanthus Nutrition 0.000 claims description 2
- 241000333181 Osmanthus Species 0.000 claims description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 2
- 230000002421 anti-septic effect Effects 0.000 claims description 2
- 235000019864 coconut oil Nutrition 0.000 claims description 2
- 239000003240 coconut oil Substances 0.000 claims description 2
- 125000003450 decanoic acid ester group Chemical group 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 claims description 2
- XJFGDLJQUJQUEI-UHFFFAOYSA-N dodecyl decanoate dodecyl octanoate Chemical compound CCCCCCCCCCCCOC(=O)CCCCCCC.CCCCCCCCCCCCOC(=O)CCCCCCCCC XJFGDLJQUJQUEI-UHFFFAOYSA-N 0.000 claims description 2
- 239000012467 final product Substances 0.000 claims description 2
- PJGSXYOJTGTZAV-UHFFFAOYSA-N pinacolone Chemical compound CC(=O)C(C)(C)C PJGSXYOJTGTZAV-UHFFFAOYSA-N 0.000 claims description 2
- 239000012747 synergistic agent Substances 0.000 claims description 2
- 244000044822 Simmondsia californica Species 0.000 claims 1
- 239000010495 camellia oil Substances 0.000 claims 1
- 229940119170 jojoba wax Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 37
- 230000037303 wrinkles Effects 0.000 abstract description 14
- 230000001153 anti-wrinkle effect Effects 0.000 abstract description 12
- 230000001737 promoting effect Effects 0.000 abstract description 7
- 108010035532 Collagen Proteins 0.000 abstract description 6
- 102000008186 Collagen Human genes 0.000 abstract description 6
- 229920001436 collagen Polymers 0.000 abstract description 6
- 230000000638 stimulation Effects 0.000 abstract description 6
- 230000002195 synergetic effect Effects 0.000 abstract description 4
- 230000003064 anti-oxidating effect Effects 0.000 abstract description 3
- 239000003795 chemical substances by application Substances 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 2
- 238000009776 industrial production Methods 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 40
- 230000000052 comparative effect Effects 0.000 description 14
- 230000032683 aging Effects 0.000 description 12
- 230000003020 moisturizing effect Effects 0.000 description 9
- 239000000341 volatile oil Substances 0.000 description 8
- 241000221095 Simmondsia Species 0.000 description 7
- 230000002051 biphasic effect Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 230000001815 facial effect Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 230000002087 whitening effect Effects 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 239000002537 cosmetic Substances 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 4
- 206010040880 Skin irritation Diseases 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 230000001242 postsynaptic effect Effects 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 230000036556 skin irritation Effects 0.000 description 4
- 231100000475 skin irritation Toxicity 0.000 description 4
- 230000036555 skin type Effects 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000037319 collagen production Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 206010013786 Dry skin Diseases 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 208000003351 Melanosis Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 229960003966 nicotinamide Drugs 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 231100000344 non-irritating Toxicity 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000003518 presynaptic effect Effects 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 230000008591 skin barrier function Effects 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 230000036560 skin regeneration Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000037331 wrinkle reduction Effects 0.000 description 2
- QICSJONFPONRPS-UHFFFAOYSA-N 2-hydroxyethyl piperazine-1-sulfonate Chemical compound OCCOS(=O)(=O)N1CCNCC1 QICSJONFPONRPS-UHFFFAOYSA-N 0.000 description 1
- 208000020154 Acnes Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 108010017377 Collagen Type VII Proteins 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 101000684826 Homo sapiens Sodium channel protein type 2 subunit alpha Proteins 0.000 description 1
- 101000693993 Homo sapiens Sodium channel protein type 4 subunit alpha Proteins 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- 108010088225 Nestin Proteins 0.000 description 1
- 102000008730 Nestin Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000235342 Saccharomycetes Species 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 102100023150 Sodium channel protein type 2 subunit alpha Human genes 0.000 description 1
- 241000519995 Stachys sylvatica Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000003679 aging effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 108010044493 collagen type XVII Proteins 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 210000005055 nestin Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000037312 oily skin Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000011506 response to oxidative stress Effects 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 208000010744 skin desquamation Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 230000037393 skin firmness Effects 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 238000005979 thermal decomposition reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9728—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Tropical Medicine & Parasitology (AREA)
- Emergency Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
本申请涉及护肤品技术领域,具体公开了一种抗衰组合物及其应用,所述抗衰组合物包括植物提取物、活性肽和其它活性成分;所述抗衰组合物在抗衰产品中应用;所述抗衰产品包括抗衰组合物、润肤油脂、防腐剂、增效剂、溶剂;本申请提出的抗衰组合物,成分天然安全、无刺激,抗衰效果显著,组合使用后能够源头针对初始表情纹,促进胶原蛋白生成,恢复皮肤结构活力;同时具有显著的抗氧化作用,能够清除机体内自由基,对抗皱具有协同增效的作用;本申请将润肤油脂、防腐剂、增效剂和溶剂加热搅拌至完全溶解,停止加热继续搅拌降至室温,加抗衰组合物继续搅拌混匀,得所需抗衰产品;其成分天然安全、无刺激,抗衰效果显著,制备方法简单,适合工业化生产。
Description
技术领域
本申请涉及护肤品技术领域,更具体地说,它涉及一种抗衰组合物及其应用。
背景技术
皮肤作为人体最大的器官,同时也作为人体的第一道防线,在保护人体器官不受外界损伤的同时也经历着内源性和外源性的老化,而皱纹就是皮肤老化最明显的标志。
影响皮肤老化的因素有很多,具体的:皮肤屏障损伤会导致皮肤屏障功能受损,无法抵御外界的刺激也无法维持皮肤正常含水量,进而加快皮肤老化;皮肤组织细胞随着年龄的增加也会发生结构和功能的衰退,表现为弹力纤维和胶原纤维流失,皮肤的机械力和弹性下降;同时皮肤细胞遭受着自由基的攻击,诸多细胞代谢废物不能被及时的清除,这些因素都会进一步增加细胞的损伤和老化;另外生活与工作压力、环境污染、生活作息不正常、长时间面对电脑、不良情绪等不可避免的问题,都会使面部皮肤粗糙干燥、产生情绪纹、皱纹和面部下垂等情况。综上所述,面部抗衰(或抗皱)的机理并不是单一的,要想实现明显的抗衰(或抗皱)效果,因从多方面因素考虑。
目前市售的抗衰产品一般只从一个方面进行抗衰(或抗皱),例如只抗氧化或者只促进胶蛋白生成,而且由于皮肤独特的屏障功能,很多活性成分只能作用于皮肤最外层降低外源性老化影响,很难透过表皮来改善内源性老化的问题。在“以油养肤”趋势下,消费者们认识到精华油是一种富含浓缩高营养成分,且更容易被皮肤吸收,能滋养皮肤的一类产品。但仍有很多水溶性的活性成分无法存在于单一纯油体系中,无法兼顾精华油的抗衰(或抗皱)等功效;而且由于肤质不同,有些精华油对于油性皮肤来说过于油腻,而对于干性皮肤来说滋润度又不够。
因此,针对目前抗衰(或抗皱)产品的不足,开发一种具有多维抗衰(或抗皱)功效的产品,以满足各类肤质使用,是本领域技术人员急需解决的技术问题。基于上述陈述,本申请提供了一种抗衰组合物及其应用。
发明内容
为了解决当前抗衰产品功效单一,很难透过表皮改善内源性老化问题,不具备多维抗衰效果等问题,本申请提供了一种抗衰组合物及其应用。
第一方面,本申请提供了一种抗衰组合物,采用如下的技术方案:
一种抗衰组合物,包括原料植物提取物2-12重量份和活性肽2-12重量份;
所述植物提取物为姜黄根提取物、松蕈提取物、沉香提取物、樟树叶提取物、黑灵芝提取物、桂花花提取物、千日菊提取物中的至少一种;
所述活性肽为精氨酸/赖氨酸多肽、乙酰基六肽-1、棕榈酰三肽-1、棕榈酰四肽-7、棕榈酰五肽-4和肌肽的复配物。
通过采用上述技术方案,本申请选用植物提取物和活性肽复配获得抗衰组合物;植物提取物中的姜黄根提取物有很好的抗炎能力和优秀的持水能力,可防治各种皮肤疾患,并起到柔润皮肤的效果;松蕈提取物能够直接清除活性氧自由基,保护皮肤细胞的DNA,保护线粒体免受UVA损伤,起到改善细纹、减少皱纹的功效;沉香提取物具有紧致修护、抗皱去细纹、美白淡斑、消炎控油等功效;樟树叶提取物能杀菌防粉刺,提高皮肤的排毒能力,加快皮肤代谢;黑灵芝提取物具有舒缓肌肤、提亮肤色、补水保湿,抑制黑色素生成等功效;桂花花提取物具有抗氧、抗炎、活肤等作用;千日菊提取物能够作用于皮肤深层的细胞外基质,刺激成纤维细胞活性,重建肌肤紧实度,恢复皮肤紧致和光滑。
活性肽选用精氨酸/赖氨酸多肽、乙酰基六肽-1、棕榈酰三肽-1、棕榈酰四肽-7、棕榈酰五肽-4和肌肽的复配物;其中,精氨酸/赖氨酸多肽能够特异性阻断肌肉纤维钠离子内流通道NAV1.4、NAV1.2,使肌肉动作电位不能形成,有效松弛肌肉,在不麻痹肌肉的情况下,改善局部皱纹;乙酰基六肽-1同时作用于突触前膜和后膜,突触前膜--抑制SNARE复合物的形成,进而减少乙酰胆碱的释放;突触后膜--抑制乙酰胆碱受体被激活,并调节突触后膜去极化状态,减少后膜Ca2+内流及肌球蛋白的交联滑动,从而抑制神经信号的传递;棕榈酰三肽-1和棕榈酰四肽-7能够增加胶原蛋白-I,-IV,-VII,-XVII型和巢蛋白I型,内源性恢复皮肤结构活力;棕榈酰五肽-4可以直接刺激胶原蛋白生成的信号肽,改善皮肤的粗糙度、减少细纹的数量、减少皱纹的深度和面积;肌肽能抑制糖基化反应,保护和促进胶原蛋白生成,保护皮肤免受自由基和氧化应激反应的伤害;采用本申请的活性肽,能够从源头针对初始表情纹的同时,配合内源性补充抗皱皮肤层内构成成分,并且长时保护胶原蛋白,减少糖化,延缓老化。
本申请提出的抗衰组合物,成分天然安全、无刺激,抗衰效果显著,组合使用后能够源头针对初始表情纹,促进胶原蛋白生成,恢复皮肤结构活力;同时具有显著的抗氧化作用,能够清除机体内自由基,对抗皱具有协同增效的作用。
优选的,所述抗衰组合物还包括其他活性成分1-15重量份;
所述其他活性成分为酵母菌发酵产物滤液、乳酸杆菌发酵产物、泛醇、烟酰胺、透明质酸钠、补骨脂酚、羟基频哪酮视黄酸酯中的至少一种。
通过采用上述技术方案,进一步选择添加其他活性成分,能够在进一步增强抗衰组合物抗衰效果的同时,增加润肤养肤的效果;其中,酵母菌发酵产物滤液中富含小分子氨基酸、多肽、核苷酸、维生素等天然活性成分物质,能够平衡油脂、润白淡斑、抗氧化、修护肌肤;乳酸杆菌发酵产物具有软化角质、美白保湿、抗菌抗炎等作用;泛醇能够刺激皮肤上皮细胞生长,具有镇静消炎、促进新陈代谢、加速伤口愈合,提高皮肤弹性等作用;烟酰胺具有锁水保湿、美白淡斑、抗衰老等作用;透明质酸钠具有良好的锁水保湿、清除氧自由基、促进表皮细胞增分化、促进皮肤再生等作用;补骨脂酚具有很强的抗炎、抗衰和美白等功效,可作用于角质细胞,深入皮下刺激并增强成纤维细胞活性,刺激胶原蛋白的生成,促进皮肤再生;羟基频哪酮视黄酸酯能够改善细纹和皱纹,具有抗氧化、淡化表皮色素、降低皮肤粗糙度、减少老年斑、减少皮肤脱皮、促进胶原蛋白生成等功效。
优选的,所述抗衰组合物,包括以下重量份的原料:姜黄根提取物0.2-3份、松蕈提取物0.5-2份、黑灵芝提取物0.1-2份、千日菊提取物2-4份、精氨酸/赖氨酸多肽0.5-3份、乙酰基六肽-1 1-3份、棕榈酰三肽-1 0.5-1份、棕榈酰四肽-7 0.3-1份、棕榈酰五肽-4 0.2-1份、肌肽0.2-1份、酵母菌发酵产物滤液0.1-2份、乳酸杆菌发酵产物0.2-3份、泛醇0.1-1份、烟酰胺0.2-3份、透明质酸钠0.2-1份、补骨脂酚0.5-2份、羟基频哪酮视黄酸酯0.5-2份。
通过采用上述技术方案,配方中植物提取物选用姜黄根提取物、松蕈提取物、黑灵芝提取物和千日菊提取物,上述植物提取物与活性肽协同作用,通过进一步添加酵母菌发酵产物滤液、乳酸杆菌发酵产物、泛醇、烟酰胺、透明质酸钠、补骨脂酚和羟基频哪酮视黄酸酯,制备得到的抗衰组合物可有效对抗多种诱因导致的外源性和内源性老化问题。
另外,发明人在实际实验过程中发现,限定上述植物提取物和活性肽的具体选用,不仅能够提高植物提取的抗氧化活性,还能够显著提高活性肽的稳定性,所得抗衰组合物活性成分吸收效果好,抗衰效果显著。
第二方面,本申请提供了一种抗衰组合物在抗衰产品中的应用。
优选的,所述抗衰产品为化妆品或日化用品。
优选的,所述抗衰产品为双相精华油。
第三方面,本申请提供了一种抗衰产品,采用如下的技术方案:
一种抗衰产品,包括所述的抗衰组合物。
优选的,所述抗衰产品,还包括原料润肤油脂10-45重量份、防腐剂0.5-2.5重量份、增效剂0.05-0.8重量份、溶剂10-90重量份。
优选的,所述润肤油脂包括角鲨烷、霍霍巴籽油、白池花籽油、山茶籽油、椰油醇-辛酸酯/癸酸酯、辛酸/癸酸甘油三酯中的至少一种。
通过采用上述技术方案,润肤油脂的添加一方面可以起到润肤、保湿、滋养等功能;另一方面能够稳定产品中的油溶性活性成分,维持产品的活性和稳定性;其中,角鲨烷亲和力强,抗氧化活性强,能在皮肤表面形成天然的保护屏障,具有很好的护肤效果;霍霍巴籽油可以起到滋润肌肤,缓解皮肤干燥的作用,能够给皮肤提供养分和水分;白池花籽油抗氧化活性强,能抵御热分解,稳定性强,能够维持产品油相成分的稳定和活性,在产品使用中提供丰富的质感和滋润效果,易吸收且不油腻;山茶籽油富含80%以上的不饱和脂肪酸,具有极佳的抗氧化、抗炎、抗皱、保湿等功效;椰油醇-辛酸酯/癸酸酯具有良好的铺展性和保湿效果,与皮肤的相容性极好,肤感清爽,无刺激;辛酸/癸酸甘油三酯可作为保湿补水因素的基料,有良好的铺展性,容易被皮肤吸收,无毒无刺激,对产品的均匀细腻起到很好的作用。
优选的,所述防腐剂包括对羟基苯乙酮、乙基己基甘油和1,2-戊二醇。
通过采用上述技术方案,防腐剂选用对羟基苯乙酮、乙基己基甘油和1,2-戊二醇的复配物,能够在有效延长产品保存期,防止产品变质的同时,减少防腐剂的用量,所得抗衰产品稳定性好,成分天然,安全无刺激。
优选的,所述增效剂包括羟乙基哌嗪乙烷磺酸、EDTA-2Na和甘草甜素。
通过采用上述技术方案,在抗衰产品中进一步添加羟乙基哌嗪乙烷磺酸、EDTA-2Na和甘草甜素,能够显著增强产品中活性物质的稳定性,增强产品吸收效果,以及在抗衰、保湿、美白等方面的效果。
优选的,所述溶剂包括丁二醇和去离子水。
通过采用上述技术方案,进一步在产品中添加溶剂丁二醇和水,制成双相精华油,水/油双相的设计,能够在有效维持油溶性活性成分稳定的同时,很好的维持水溶性活性成分的活性和稳定性,其适用于各类肤质,用后皮肤吸收效果好,清爽不油腻,具有优异的抗衰、保湿、美白等功效。
优选的,所述抗衰产品包括以下重量份的原料:姜黄根提取物0.2-3份、松蕈提取物0.5-2份、黑灵芝提取物0.1-2份、千日菊提取物2-4份、精氨酸/赖氨酸多肽0.5-3份、乙酰基六肽-1 1-3份、棕榈酰三肽-1 0.5-1份、棕榈酰四肽-7 0.3-1份、棕榈酰五肽-4 0.2-1份、肌肽0.2-1份、酵母菌发酵产物滤液0.1-2份、乳酸杆菌发酵产物0.2-3份、泛醇0.1-1份、烟酰胺0.2-3份、透明质酸钠0.2-1份、补骨脂酚0.5-2份、羟基频哪酮视黄酸酯0.5-2份、霍霍巴籽油1-5份、白池花籽油0.1-5份、山茶籽油0.1-5份、椰油醇-辛酸酯/癸酸酯5-15份、辛酸/癸酸甘油三酯5-15份、对羟基苯乙酮0.1-0.5份、乙基己基甘油0.2-1份、1,2-戊二醇0.2-1份、羟乙基哌嗪乙烷磺酸0.01-0.5份、EDTA-2Na 0.05-0.2份、甘草甜素0.01-0.1份、丁二醇0.5-4份、去离子水12-82份。
优选的,所述姜黄根提取物0.5份、松蕈提取物1份、黑灵芝提取物0.5份、千日菊提取物3份、精氨酸/赖氨酸多肽1.5份、乙酰基六肽-1 1.5份、棕榈酰三肽-1 0.8份、棕榈酰四肽-7 0.5份、棕榈酰五肽-4 0.2份、肌肽0.5份、酵母菌发酵产物滤液1份、乳酸杆菌发酵产物1份、泛醇0.4份、烟酰胺1.6份、透明质酸钠0.5份、补骨脂酚1.3份、羟基频哪酮视黄酸酯1.2份、霍霍巴籽油3份、白池花籽油3份、山茶籽油2份、椰油醇-辛酸酯/癸酸酯12份、辛酸/癸酸甘油三酯10份、对羟基苯乙酮0.1份、乙基己基甘油0.2份、1,2-戊二醇0.2份、羟乙基哌嗪乙烷磺酸0.3份、EDTA-2Na 0.1份、甘草甜素0.1份、丁二醇2份、去离子水50份。
通过采用上述技术方案,进一步优选本申请原料配方和配比,可进一步提高获得双相精华油的产品稳定性、活性成分吸收效果、抗衰效果等;最终获得的双相精华油性价比高,适用于各类肤质使用,安全无刺激,用后吸收效果好,可起到明显的多维抗衰效果。
第四方面,本申请提供了一种抗衰产品的制备方法,采用如下的技术方案:
一种抗衰产品的制备方法,包括以下制备步骤:
将润肤油脂、防腐剂、增效剂和溶剂加热搅拌至完全溶解,停止加热继续搅拌降温至室温,加抗衰组合物继续搅拌混匀,得所需抗衰产品。
优选的,所述抗衰产品的制备方法,具体包括以下制备步骤:
将去离子水、丁二醇、透明质酸钠、羟乙基哌嗪乙烷磺酸、EDTA-2Na和甘草甜素混合加热至75-80℃,搅拌至完全溶解混合均匀,得A相物料;
将对羟基苯乙酮、乙基己基甘油和1,2-戊二醇混合加热至75-80℃,搅拌至完全溶解混合均匀后,加入到A相物料中,搅拌混合均匀,得B相物料;
将B相物料降温至35-45℃,依次加入泛醇、烟酰胺、肌肽、酵母菌发酵产物滤液、黑灵芝提取物、松蕈提取物、乳酸杆菌发酵产物、姜黄根提取物、精氨酸/赖氨酸多肽、乙酰基六肽-1、棕榈酰三肽-1、棕榈酰四肽-7和棕榈酰五肽-4,搅拌至混合均匀,得水相混合液;
将椰油醇-辛酸酯/癸酸酯、辛酸/癸酸甘油三酯、霍霍巴籽油、白池花籽油和山茶籽油加热至75-80℃,搅拌至完全溶解混合均匀,降温至35-45℃,加入羟基频哪酮视黄酸酯、千日菊提取物和补骨脂酚,搅拌至混合均匀,得油相混合液;
将油相混合液和水相混合液混合,即得所需的抗衰产品。
通过采用上述技术方案,先分别混合水相成分和油相成分,控制原料混合温度和混合顺序,能够在保证获得均匀细腻抗衰产品的同时,最大程度的保留活性成分不受破坏,获得的产品稳定性好,保存期长,水油界面分层清晰,且外观无明显变化。
综上所述,本申请具有以下有益效果:
本申请的抗衰组合物成分天然、安全无刺激,采用植物提取物和活性肽搭配组合,协同作用,制备得到的抗衰组合物可有效对抗多种诱因导致的外源性和内源性老化问题;通过进一步添加其他活性成分,能够在进一步增强抗衰组合物抗衰效果的同时,增加润肤养肤的效果。
本申请的抗衰组合物可应用于制备抗衰产品,具体的通过添加润肤油脂、防腐剂、增效剂和溶剂,可混合制备获得多维抗衰的双相精华油,使用前需要摇匀,把两种状态液体混合一起,本申请的双相精华油可适用于各类肤质,用后吸收效果好,清爽不油腻,能够同时很好的兼顾油溶性和水溶性的活性成分,显著对抗多种诱因导致的外源性和内源性老化问题;另外,本申请的双相精华液还具有优异的滋润保湿、美白淡斑、养肤焕肤等功效。
本申请的抗衰产品成分天然、安全无刺激,其制备方法简单,制备条件温和,适合工业化生产,所得抗衰产品功效活性强,产品稳定性好,保存期长,保存期内存放,水油界面分层清晰,且外观无明显变化。
具体实施方式
以下结合实施例对本申请作进一步详细说明。实施例中,所使用的实验方法如无特殊说明,均为常规方法,所用的材料、试剂等,如无特殊说明,均可从商业途径得到。
本申请实施例1-15提供了一种抗衰产品的原料组分及质量选择,具体见表1,以产品总量为100Kg计算,实施例1-15的一种抗衰产品的制备方法,包括如下步骤:
将去离子水、丁二醇、透明质酸钠、羟乙基哌嗪乙烷磺酸、EDTA-2Na和甘草甜素混合加热至75℃,以350r/min的转速搅拌混合20min,至完全溶解混合均匀,得A相物料;
将对羟基苯乙酮、乙基己基甘油和1,2-戊二醇混合加热至75℃,以350r/min的转速搅拌混合12min,搅拌至完全溶解混合均匀后,加入到A相物料中,继续搅拌混合15min至混合均匀,得B相物料;
将B相物料降温至40℃,依次加入泛醇、烟酰胺、肌肽、酵母菌发酵产物滤液、黑灵芝提取物、松蕈提取物、乳酸杆菌发酵产物、姜黄根提取物、精氨酸/赖氨酸多肽、乙酰基六肽-1、棕榈酰三肽-1、棕榈酰四肽-7和棕榈酰五肽-4,以350r/min的转速搅拌混合30min至混合均匀,得水相混合液;
将椰油醇-辛酸酯/癸酸酯、辛酸/癸酸甘油三酯、霍霍巴籽油、白池花籽油和山茶籽油加热至75℃,以350r/min的转速搅拌混合20min,至完全溶解混合均匀,降温至40℃,加入羟基频哪酮视黄酸酯、千日菊提取物和补骨脂酚,继续搅拌混合20min至混合均匀,得油相混合液;
将油相混合液和水相混合液以350r/min的转速搅拌混合30min,混合均匀,即得所需的抗衰产品。
表1:实施例1-5、14-15提供的抗衰产品的原料组分及含量表
实施例6与实施例1相同,区别仅在于,将松蕈提取物等质量替换为千日菊提取物。
实施例7与实施例1相同,区别仅在于,将甘草甜素等质量替换为羟乙基哌嗪乙烷磺酸。
实施例8与实施例1相同,区别仅在于,将甘草甜素等质量替换为EDTA-2Na。
实施例9与实施例1相同,区别仅在于,将羟乙基哌嗪乙烷磺酸等质量用甘草甜素。
实施例10与实施例1相同,区别仅在于,将甘草甜素、EDTA-2Na等质量替换为羟乙基哌嗪乙烷磺酸。
实施例11与实施例1相同,区别仅在于,将甘草甜素、羟乙基哌嗪乙烷磺酸等质量替换为EDTA-2Na。
实施例12与实施例1相同,区别仅在于,将羟乙基哌嗪乙烷磺酸、EDTA-2Na等质量替换为甘草甜素。
实施例13与实施例1相同,区别仅在于,将增效剂等质量替换其他相应质量比的原料。
对比例1-6提供了一种抗衰产品,具体如下:
对比例1与实施例1相同,区别仅在于,将精氨酸/赖氨酸多肽等质量替换为乙酰基六肽-1。
对比例2与实施例1相同,区别仅在于,将乙酰基六肽-1等质量替换为精氨酸/赖氨酸多肽。
对比例3与实施例1相同,区别仅在于,将棕榈酰五肽-4等质量替换为肌肽。
对比例4与实施例1相同,区别仅在于,将肌肽等质量替换为棕榈酰五肽-4。
对比例5与实施例1相同,区别仅在于,千日菊提取物等质量替换为去离子水。
对比例6与实施例1相同,区别仅在于,乙酰基六肽-1等质量替换为去离子水。
产品性能测试
一、安全性测试
皮肤刺激性/腐蚀性实验(多次皮肤刺激性实验)及产品安全性评价
取本发明实施例1-15和对比例1-6中制备得到的抗衰产品按照《化妆品卫生规范》(2007版)的皮肤刺激性/腐蚀性试验进行测试评价,安全性评价按照《化妆品安全技术规范》(2015版)人体斑贴实验进行评价,评价结果显示多次皮肤刺激试验结果为无刺激,斑贴试验结果均为阴性。
结果证明本申请的抗衰产品对人体无刺激性、无致敏性、无其他不良反应。
二、理化测试
(1)加速稳定性
取适量本申请实施例1-15和对比例1-6中的抗衰产品于离心管中,密封管口,3000rpm离心30min;
观察发现本申请的抗衰产品未观察到悬浮物、沉淀现象。
(2)变温稳定性
取适量本申请实施例1-15和对比例1-6中的抗衰产品,分别置于4℃、25℃、37℃、60℃的环境中考察3个月,每周取样观察,结果发现本申请的抗衰产品在此四种稳定条件下均保持澄清透明的外观,未出现悬浮物、沉淀现象。
(3)微生物检验
将本申请实施例1-15和对比例1-6中的抗衰产品的微生物检测实验按照《化妆品安全技术规范》(2015版)中的微生物检测方法进行测试,测试结果如下表2。
表2:
从表2实验结果可以得出:本申请抗衰产品的菌落总数、霉菌和酵母菌总数、耐热大肠菌群、金黄色葡萄球菌、铜绿假单胞菌均符合《化妆品安全技术规范》(2015版)对微生物指标的要求。
三、功效性评价(VISIA拍照)
邀请年龄为35-55岁之间,眼周有细纹,想美化面部轮廓线的体验官150名,体验官均为自愿参与的健康女性。
将体验官平均分为15组,每组10人,每天一次,搭配相同的按摩手法分别于洁面后均匀涂抹本申请实施例1-15和对比例1-6中的抗衰产品。
分别于第一次使用前,第一次使用后(120min时),连续使用一个月且停用一星期后,用VISIA-7进行面部图像采集,记录志愿者的面部情况,计算相对于第一次使用前,第一次使用后(120min时),以及连续使用一个月且停用一星期后的平均眼部皱纹减少率,对本申请抗衰产品的抗皱效果进行评价,结果如表3所示。
皱纹减少率/%=(使用前皱纹量-使用后皱纹量)÷使用前皱纹量×100%。
表3:
由上述表3显示数据可知:具体的由本申请实施例1-15可知,在本申请优选的配方范围内,随着抗衰产品中植物提取物、活性肽等活性成分质量的增加,制得的抗衰产品的抗皱效果明显改善。进一步的由实施例2-4可知,植物提取物、活性肽等活性成分总用量不变,仅改变具体选用成分的用量,对抗衰产品效果影响不明显,总体效果较好。进一步的由实施例5可知,活性成分多,油多,水少,带来的效果也最为优异。
由实施例6、对比例1-4和实施例1可知:在保证植物提取物或活性肽总质量不变的情况下,减少其中一种组分的选用,抗皱效果会出现明显下降,同时抗皱持续效果较差。
由实施例7-13和实施例1可知:在保证增效剂总质量不变的情况下,采用羟乙基哌嗪乙烷磺酸、EDTA-2Na和甘草甜素复配较仅选用其中的任意两种或任意一种,最终制得的抗衰产品的抗衰效果会有显著的提升。
由对比例5-6和实施例1可知:抗衰产品中抗衰组合物用量降低至本申请优选范围外后,最终制得抗衰产品的抗衰效果,出现明显下降。
由实施例5和实施例14-15可知:当水相混合液和油相混合液的比例为8:2时,所带来的抗衰效果较为优异,而调整白池花籽油和山茶籽油的比例使油相混合液占比增大,或调整霍霍巴籽油的比例使油相混合液占比减小,均会导致抗衰效果有明显的损失。由此可见,水相混合液和油相混合液的质量混合比为8:2时,更有利于抗衰产品中植物提取物、活性肽等活性成分配合并发挥出优异作用效果。
具体实施例仅仅是对本申请的解释,其并不是对本申请的限制,本领域技术人员在阅读完本说明书后可以根据需要对本实施例做出没有创造性贡献的修改,但只要在本申请的权利要求范围内都受到专利法的保护。
Claims (10)
1.一种抗衰组合物,其特征在于,包括原料植物提取物2-12重量份和活性肽2-12重量份;
所述植物提取物为姜黄根提取物、松蕈提取物、沉香提取物、樟树叶提取物、黑灵芝提取物、桂花花提取物、千日菊提取物中的至少一种;
所述活性肽为精氨酸/赖氨酸多肽、乙酰基六肽-1、棕榈酰三肽-1、棕榈酰四肽-7、棕榈酰五肽-4和肌肽的复配物。
2.根据权利要求1所述的抗衰组合物,其特征在于,所述抗衰组合物还包括其他活性成分1-15重量份;
所述其他活性成分为酵母菌发酵产物滤液、乳酸杆菌发酵产物、泛醇、烟酰胺、透明质酸钠、补骨脂酚、羟基频哪酮视黄酸酯中的至少一种。
3.根据权利要求2所述的抗衰组合物,其特征在于,包括以下重量份的原料:姜黄根提取物0.2-3份、松蕈提取物0.5-2份、黑灵芝提取物0.1-2份、千日菊提取物2-4份、精氨酸/赖氨酸多肽0.5-3份、乙酰基六肽-1 1-3份、棕榈酰三肽-1 0.5-1份、棕榈酰四肽-7 0.3-1份、棕榈酰五肽-4 0.2-1份、肌肽0.2-1份、酵母菌发酵产物滤液0.1-2份、乳酸杆菌发酵产物0.2-3份、泛醇0.1-1份、烟酰胺0.2-3份、透明质酸钠0.2-1份、补骨脂酚0.5-2份、羟基频哪酮视黄酸酯0.5-2份。
4.一种权利要求1-3任一项所述的抗衰组合物在抗衰产品中的应用。
5.一种抗衰产品,其特征在于,所述抗衰产品包括权利要求1-3任一项所述的抗衰组合物。
6.根据权利要求5所述的抗衰产品,其特征在于,还包括原料润肤油脂10-45重量份、防腐剂0.5-2.5重量份、增效剂0.05-0.8重量份、溶剂10-90重量份。
7.根据权利要求6所述的抗衰产品,其特征在于,所述润肤油脂包括角鲨烷、霍霍巴籽油、白池花籽油、山茶籽油、椰油醇-辛酸酯/癸酸酯、辛酸/癸酸甘油三酯中的至少一种;
所述防腐剂包括对羟基苯乙酮、乙基己基甘油和1,2-戊二醇;
所述增效剂包括羟乙基哌嗪乙烷磺酸、EDTA-2Na和甘草甜素;
所述溶剂包括丁二醇和去离子水。
8.根据权利要求7所述的抗衰产品,其特征在于,包括以下重量份的原料:姜黄根提取物0.2-3份、松蕈提取物0.5-2份、黑灵芝提取物0.1-2份、千日菊提取物2-4份、精氨酸/赖氨酸多肽0.5-3份、乙酰基六肽-1 1-3份、棕榈酰三肽-1 0.5-1份、棕榈酰四肽-7 0.3-1份、棕榈酰五肽-4 0.2-1份、肌肽0.2-1份、酵母菌发酵产物滤液0.1-2份、乳酸杆菌发酵产物0.2-3份、泛醇0.1-1份、烟酰胺0.2-3份、透明质酸钠0.2-1份、补骨脂酚0.5-2份、羟基频哪酮视黄酸酯0.5-2份、霍霍巴籽油1-5份、白池花籽油0.1-5份、山茶籽油0.1-5份、椰油醇-辛酸酯/癸酸酯5-15份、辛酸/癸酸甘油三酯5-15份、对羟基苯乙酮0.1-0.5份、乙基己基甘油0.2-1份、1,2-戊二醇0.2-1份、羟乙基哌嗪乙烷磺酸0.01-0.5份、EDTA-2Na 0.05-0.2份、甘草甜素0.01-0.1份、丁二醇0.5-4份、去离子水12-82份。
9.一种权利要求6-8任一项所述的抗衰产品的制备方法,其特征在于,包括以下制备步骤:
将润肤油脂、防腐剂、增效剂和溶剂加热搅拌至完全溶解,停止加热继续搅拌降温至室温,加抗衰组合物继续搅拌混匀,得所需抗衰产品。
10.根据权利要求9所述的抗衰产品的制备方法,其特征在于,具体包括以下制备步骤:
将去离子水、丁二醇、透明质酸钠、羟乙基哌嗪乙烷磺酸、EDTA-2Na和甘草甜素混合加热至75-80℃,搅拌至完全溶解混合均匀,得A相物料;
将对羟基苯乙酮、乙基己基甘油和1,2-戊二醇混合加热至75-80℃,搅拌至完全溶解混合均匀后,加入到A相物料中,搅拌混合均匀,得B相物料;
将B相物料降温至35-45℃,依次加入泛醇、烟酰胺、肌肽、酵母菌发酵产物滤液、黑灵芝提取物、松蕈提取物、乳酸杆菌发酵产物、姜黄根提取物、精氨酸/赖氨酸多肽、乙酰基六肽-1、棕榈酰三肽-1、棕榈酰四肽-7和棕榈酰五肽-4,搅拌至混合均匀,得水相混合液;
将椰油醇-辛酸酯/癸酸酯、辛酸/癸酸甘油三酯、霍霍巴籽油、白池花籽油和山茶籽油加热至75-80℃,搅拌至完全溶解混合均匀,降温至35-45℃,加入羟基频哪酮视黄酸酯、千日菊提取物和补骨脂酚,搅拌至混合均匀,得油相混合液;
将油相混合液和水相混合液混合,即得所需的抗衰产品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310608412.2A CN116617132A (zh) | 2023-05-27 | 2023-05-27 | 一种抗衰组合物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310608412.2A CN116617132A (zh) | 2023-05-27 | 2023-05-27 | 一种抗衰组合物及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116617132A true CN116617132A (zh) | 2023-08-22 |
Family
ID=87612973
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310608412.2A Pending CN116617132A (zh) | 2023-05-27 | 2023-05-27 | 一种抗衰组合物及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116617132A (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115531276A (zh) * | 2022-11-09 | 2022-12-30 | 江西沁华蔓医药科技有限公司 | 透皮保湿精华液及其制备方法 |
CN115607475A (zh) * | 2022-09-15 | 2023-01-17 | 广州市小谭科技有限公司 | 一种抗衰去皱复合多肽组合物及其应用 |
CN116035987A (zh) * | 2022-10-10 | 2023-05-02 | 上海栩霏化妆品有限公司 | 一种小分子肽多元组合物及含其护肤品 |
-
2023
- 2023-05-27 CN CN202310608412.2A patent/CN116617132A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115607475A (zh) * | 2022-09-15 | 2023-01-17 | 广州市小谭科技有限公司 | 一种抗衰去皱复合多肽组合物及其应用 |
CN116035987A (zh) * | 2022-10-10 | 2023-05-02 | 上海栩霏化妆品有限公司 | 一种小分子肽多元组合物及含其护肤品 |
CN115531276A (zh) * | 2022-11-09 | 2022-12-30 | 江西沁华蔓医药科技有限公司 | 透皮保湿精华液及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110742842B (zh) | 一种延缓皮肤老化的精华组合物及其制备方法 | |
CN110623882A (zh) | 一种美白祛斑面膜及其制备方法 | |
WO2002015860A1 (en) | Topical antioxidant having vitamin c and method of combination with topical agent by user | |
CN110664644B (zh) | 一种含叶酸的护肤组合物、精华及其制备方法 | |
CN110638707A (zh) | 一种眼部护理霜及其制备方法 | |
CN113576975B (zh) | 一种易吸收的抗衰老组合物及其制备方法和应用 | |
WO2012070835A2 (ko) | 모자반 추출물, 청각 추출물 및 참미역 추출물을 함유하는 화장료 조성물 | |
CN116549373A (zh) | 一种平衡皮肤油脂分泌的组合物及其制备方法和应用 | |
KR20090038648A (ko) | 편백 오일를 함유한 여드름 피부용 화장료 조성물 | |
CN111803422A (zh) | 一种控油组合物及其应用 | |
CN108852976B (zh) | 一种晶润滋养乳 | |
CN110693778A (zh) | 一种面霜及其生产工艺 | |
CN116850114B (zh) | 一种舒缓修复组合物及舒缓修复乳 | |
CN111743826A (zh) | 一种祛斑抗皱保湿乳液 | |
CN113633575A (zh) | 一种提亮肤色组合物及其精华液的制备方法 | |
CN111759762A (zh) | 祛黑眼圈组合物、精华及其制备方法 | |
CN116459169A (zh) | 一种抗炎保湿皮肤外用组合物及其制备方法和应用 | |
KR101587077B1 (ko) | 피부 생리활성을 가지는 백년초 발효물을 포함하는 조성물 | |
CN116139053A (zh) | 一种祛痘修护组合物、化妆品及其制备方法和应用 | |
CN116617132A (zh) | 一种抗衰组合物及其应用 | |
CH700735B1 (de) | Kosmetische Komposition für die Verjüngung des Erscheinungsbildes der Haut. | |
CN112402335A (zh) | 一种爆水散粉及其制备方法 | |
CN110721102A (zh) | 一种具有保湿抗皱抗氧化作用的眼膜 | |
CN116869855B (zh) | 含有胶原蛋白的皮肤修护组合物 | |
CN110755343A (zh) | 一种老年乳液及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20230822 |